DK1601670T3 - Arylvinylazacycloalkanforbindelser og fremgangsmåder til fremstilling og anvendelse deraf - Google Patents

Arylvinylazacycloalkanforbindelser og fremgangsmåder til fremstilling og anvendelse deraf

Info

Publication number
DK1601670T3
DK1601670T3 DK04717398T DK04717398T DK1601670T3 DK 1601670 T3 DK1601670 T3 DK 1601670T3 DK 04717398 T DK04717398 T DK 04717398T DK 04717398 T DK04717398 T DK 04717398T DK 1601670 T3 DK1601670 T3 DK 1601670T3
Authority
DK
Denmark
Prior art keywords
azacycloalkane
arylvinyl
compounds
processes
preparation
Prior art date
Application number
DK04717398T
Other languages
English (en)
Inventor
Jeffrey Daniel Schmitt
Gary Maurice Dull
Arielle Genevois-Borella
Marc Capet
Michel Cheve
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Application granted granted Critical
Publication of DK1601670T3 publication Critical patent/DK1601670T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04717398T 2003-03-05 2004-03-04 Arylvinylazacycloalkanforbindelser og fremgangsmåder til fremstilling og anvendelse deraf DK1601670T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof
PCT/US2004/006530 WO2004078752A1 (en) 2003-03-05 2004-03-04 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
DK1601670T3 true DK1601670T3 (da) 2008-08-25

Family

ID=32926772

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04717398T DK1601670T3 (da) 2003-03-05 2004-03-04 Arylvinylazacycloalkanforbindelser og fremgangsmåder til fremstilling og anvendelse deraf
DK09075124.9T DK2085395T3 (da) 2003-03-05 2004-03-04 Arylvinylazacycloalkan-forbindelser og fremgangsmåder til fremstilling og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09075124.9T DK2085395T3 (da) 2003-03-05 2004-03-04 Arylvinylazacycloalkan-forbindelser og fremgangsmåder til fremstilling og anvendelser deraf

Country Status (32)

Country Link
US (8) US7098331B2 (da)
EP (3) EP2085395B1 (da)
JP (3) JP4663627B2 (da)
KR (4) KR101185541B1 (da)
CN (3) CN100526308C (da)
AR (3) AR043469A1 (da)
AT (3) ATE496046T1 (da)
AU (3) AU2004217903B2 (da)
BR (1) BRPI0409576A (da)
CA (1) CA2516514C (da)
CL (1) CL2004000452A1 (da)
CY (2) CY1110391T1 (da)
DE (2) DE602004013553D1 (da)
DK (2) DK1601670T3 (da)
EA (3) EA014714B1 (da)
ES (3) ES2389106T3 (da)
GT (1) GT200400033A (da)
HK (3) HK1084949A1 (da)
IL (3) IL170155A (da)
JO (1) JO2488B1 (da)
MX (1) MXPA05009386A (da)
NO (3) NO331920B1 (da)
NZ (1) NZ541795A (da)
PA (1) PA8597201A1 (da)
PE (1) PE20040930A1 (da)
PL (5) PL2085395T3 (da)
PT (2) PT1601670E (da)
SI (2) SI2085395T1 (da)
TW (3) TWI339662B (da)
UY (1) UY28218A1 (da)
WO (1) WO2004078752A1 (da)
ZA (1) ZA200506790B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
EP2647373A1 (en) * 2008-05-12 2013-10-09 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine.
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
IL266097B (en) * 2008-12-01 2022-07-01 Oyster Point Pharma Inc Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
MX2011013860A (es) * 2009-06-17 2012-01-30 Targacept Inc Inversion de la discinesia inducida por levopoda mediante los ligandos del receptor nicotinico neural.
AU2010328419A1 (en) 2009-12-07 2012-06-21 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
JP2013522201A (ja) * 2010-03-11 2013-06-13 ターガセプト，インコーポレイテッド 便秘のためのアリールビニルアザシクロアルカン化合物
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
KR102485299B1 (ko) 2016-04-07 2023-01-06 오이스터 포인트 파마 인코포레이티드 안구 장애의 치료 방법
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
WO2020014232A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
WO1999021834A1 (en) 1997-10-27 1999-05-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
WO2000075110A1 (en) 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
MXPA02002115A (es) 1999-09-14 2002-10-31 Abbott Lab Compuestos de eter 3-pirrolidiniloxi-3'-piridilico, utiles para controlar la transmision sinaptica quimica. .
JP2003513054A (ja) 1999-11-01 2003-04-08 ターガセプト，インコーポレイテッド アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
AU2002322562A1 (en) 2001-07-19 2003-03-03 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
HK1130254A1 (en) 2009-12-24
NZ541795A (en) 2008-03-28
TW200505909A (en) 2005-02-16
IL170155A (en) 2013-08-29
NO20054120D0 (no) 2005-09-05
EP2085395A1 (en) 2009-08-05
GT200400033A (es) 2005-05-29
EP1947100A1 (en) 2008-07-23
JP2006519868A (ja) 2006-08-31
US20100010042A1 (en) 2010-01-14
IL197889A (en) 2013-03-24
CY1111615T1 (el) 2015-10-07
US8067443B2 (en) 2011-11-29
US8063068B2 (en) 2011-11-22
US7098331B2 (en) 2006-08-29
SI2085395T1 (sl) 2011-05-31
US20100267776A1 (en) 2010-10-21
EA010870B1 (ru) 2008-12-30
IL197890A (en) 2013-11-28
AU2008258188B2 (en) 2011-02-24
CN101255155A (zh) 2008-09-03
CN101550132B (zh) 2012-03-28
EA200801764A1 (ru) 2008-12-30
KR101018083B1 (ko) 2011-03-02
PT1601670E (pt) 2008-07-11
KR101185541B1 (ko) 2012-09-24
EA019240B1 (ru) 2014-02-28
TWI377204B (en) 2012-11-21
JP4663627B2 (ja) 2011-04-06
DE602004013553D1 (de) 2008-06-19
US8633222B2 (en) 2014-01-21
PL2085395T3 (pl) 2011-05-31
TW200927745A (en) 2009-07-01
TW200927746A (en) 2009-07-01
CA2516514A1 (en) 2004-09-16
EA200900706A1 (ru) 2009-10-30
MXPA05009386A (es) 2005-11-04
CA2516514C (en) 2012-02-07
US20110152293A1 (en) 2011-06-23
US20060094732A1 (en) 2006-05-04
NO331920B1 (no) 2012-04-30
KR20090021228A (ko) 2009-02-27
PL394600A1 (pl) 2011-07-18
CN101550132A (zh) 2009-10-07
NO20054120L (no) 2005-10-03
HK1084949A1 (en) 2006-08-11
US7714001B2 (en) 2010-05-11
JO2488B1 (en) 2009-10-05
KR20120014236A (ko) 2012-02-16
PE20040930A1 (es) 2005-02-18
PL1601670T3 (pl) 2008-10-31
WO2004078752A1 (en) 2004-09-16
DE602004031165D1 (de) 2011-03-03
US20040176348A1 (en) 2004-09-09
TWI339662B (en) 2011-04-01
JP5537085B2 (ja) 2014-07-02
ATE496046T1 (de) 2011-02-15
NO20091888L (no) 2005-10-03
EA014714B1 (ru) 2011-02-28
CN100526308C (zh) 2009-08-12
ZA200506790B (en) 2006-05-31
BRPI0409576A (pt) 2006-04-18
SI1601670T1 (sl) 2008-10-31
AU2004217903A1 (en) 2004-09-16
ES2389106T3 (es) 2012-10-23
EA200501425A1 (ru) 2006-02-24
AU2008258188A1 (en) 2009-01-15
HK1116800A1 (en) 2009-01-02
DK2085395T3 (da) 2011-04-18
PT2085395E (pt) 2011-04-20
ES2385941T3 (es) 2012-08-03
KR100953150B1 (ko) 2010-04-19
US20150164894A1 (en) 2015-06-18
AR070570A2 (es) 2010-04-21
PL216979B1 (pl) 2014-06-30
CN1756754A (zh) 2006-04-05
ATE394394T1 (de) 2008-05-15
UY28218A1 (es) 2005-06-30
PL394604A1 (pl) 2011-07-18
EP1601670B1 (en) 2008-05-07
EP1601670A1 (en) 2005-12-07
EP1947100B1 (en) 2011-07-27
KR20090021227A (ko) 2009-02-27
JP5537084B2 (ja) 2014-07-02
EP2085395B1 (en) 2011-01-19
ES2309507T3 (es) 2008-12-16
KR20060006006A (ko) 2006-01-18
PL215059B1 (pl) 2013-10-31
PL378415A1 (pl) 2006-04-03
PA8597201A1 (es) 2004-09-28
US20140107164A1 (en) 2014-04-17
NO332293B1 (no) 2012-08-20
JP2009292825A (ja) 2009-12-17
NO20092231L (no) 2005-10-03
AU2008258187A1 (en) 2009-01-15
AU2004217903B2 (en) 2010-03-04
CL2004000452A1 (es) 2005-05-20
AR043469A1 (es) 2005-07-27
AU2008258187B2 (en) 2010-08-05
AR070569A2 (es) 2010-04-21
CY1110391T1 (el) 2015-04-29
ATE517893T1 (de) 2011-08-15
JP2010001296A (ja) 2010-01-07
US20080293778A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
NO20054120D0 (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
CY2023008I1 (el) Χημικες ενωσεις
IS2935B (is) Misnotkunarvarið lyfjaform til skömmtunar um húð
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
IS8320A (is) N-staðgengnir pýrasólýl-amidýl-bensimidasólýl
NO20055459D0 (no) Prosesser
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
DE602004031845D1 (de) Ng
DK1575618T3 (da) Dispergerbare farmaceutiske kombinationer
ATE363895T1 (de) Zubereitungen enthaltend sucralose
ATE469878T1 (de) Aminobenzophenonverbindungen
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
DE50204020D1 (de) Mikrotom
DK1587478T3 (da) Farmaceutisk sammensætning
SE0302091L (sv) Genomföring
DE502004002225D1 (de) Selbstemulgierende Zubereitungen
DE602004014804D1 (de) Haltenden tabletten
DE602004018799D1 (de) Ng
DK1662867T3 (da) Insekticid-forbindelser og fremgangsmåder til valg deraf
DE602004014239D1 (de) Betoniereinrichtung
NO20053805D0 (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
DK1639107T3 (da) Forbedrede proteaser og fremgangsmåder til fremstilling deraf
ATE514681T1 (de) N-substituierte pyrazolylcarboxanilide
DE60328306D1 (de) Drucktuch
NO20034952D0 (no) Farmasöytiske forbindelser